Sub-nanomolar sensitivity of nitric oxide mediated regulation of cGMP and vasomotor reactivity in vascular smooth muscle

Frontiers in Pharmacology

Volumn 3 JUL, Issue , 2012, Pages

  Held, Kara F ^a,b   Dostmann, Wolfgang R ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cGMP; Nitric oxide; Phosphodiesterase; Soluble guanylyl cyclase; Vasodilation

Indexed keywords

CYCLIC GMP; GUANYLATE CYCLASE; NITRIC OXIDE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE V;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOSENSOR; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CONTROLLED STUDY; ENZYME KINETICS; FLUORESCENCE MICROSCOPY; HOMEOSTASIS; HUMAN; HUMAN CELL; HYDROLYSIS; MALE; MEMBRANE PERMEABILITY; MOUSE; MYOGRAPHY; NONHUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; RAT; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; VASODILATATION; VASOMOTOR REFLEX;

EID: 84866174260     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00130     Document Type: Article

References (50)

1. Amezcua, J. L., Dusting, G. J., Palmer, R. M., and Moncada, S. (1988). Acetyl-choline induces vasodilatation in the rabbit isolated heart through the release of nitric oxide, the endogenous nitrovasodilator. Br. J. Pharmacol. 95, 830-834.
2. Arnold, W. P., Mittal, C. K., Katsuki, S., and Murad, F. (1977). Nitric oxide activates guanylate cyclase and increases guanosine 3';:5';-cyclic monophosphate levels in various tissue preparations. Proc. Natl. Acad. Sci. U.S.A. 74, 3203-3207.
3. Artz, J. D., Toader, V., Zavorin, S. I., Bennett, B. M., and Thatcher, G. R. (2001). In vitro activation of soluble guanylyl cyclase and nitric oxide release: a comparison of NO donors and NO mimetics. Biochemistry 40, 9256-9264.
4. Batchelor, A. M., Bartus, K., Reynell, C., Constantinou, S., Halvey, E. J., Held, K. F., Dostmann, W. R., Vernon, J., and Garthwaite, J. (2010). Exquisite sensitivity to subsecond, pico-molar nitric oxide transients conferred on cells by guanylyl cyclase-coupled receptors. Proc. Natl Acad. Sci. U.S.A. 107,22060-22065.
5. Bellamy, T. C., and Garthwaite, J. (2001). Sub-second kinetics of the nitric oxide receptor, soluble guanylyl cyclase, in intact cere-bellar cells. J. Biol. Chem. 276, 4287-4292.
6. Bellamy, T. C., Griffiths, C., and Garthwaite, J. (2002). Differential sensitivity of guanylyl cyclase and mitochondrial respiration to nitric oxide measured using clamped concentrations. J. Biol Chem. 277, 31801-31807.
7. Bellamy, T. C., Wood, J., Goodwin, D. A., and Garthwaite, J. (2000). Rapid desensitization of the nitric oxide receptor, soluble guanylyl cyclase, underlies diversity of cellular cGMP responses. Proc. Natl Acad. Sci. U.S.A. 97,2928-2933.
8. Bender, A. T., and Beavo, J. A. (2006). Cyclic nucleotide phospho-diesterases: molecular regulation to clinical use. Pharmacol Rev. 58, 488-520.
9. Bischoff, E. (2004). Potency, selectivity, and consequences of nonse-lectivity of PDE inhibition. Int. I Impot. Res. 16(Suppl. 1), S11-S14.
10. Cawley, S. M., Sawyer, C. L., Brunelle, K. F., Van Der Vliet, A., and Dostmann, W. R. (2007). Nitric oxide-evoked transient kinetics of cyclic GMP in vascular smooth muscle cells. Cell. Signal. 19, 1023-1033.
11. Cocks, T. M., Angus, J. A., Campbell, J. H., and Campbell, G. R. (1985). Release and properties of endothelium-derived relaxing factor (EDRF) from endothelial cells in culture.J. Cell. Physiol. 123,310-320.
12. Conti, M., Nemoz, G., Sette, C., and Vicini, E. (1995). Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr. Rev. 16, 370-389.
13. Corbin, J. D., Turko, I. V., Beasley, A., and Francis, S. H. (2000). Phos-phorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur. J. Biochem. 267,2760-2767.
14. Derbyshire, E. R., and Marletta, M. A. (2009). Biochemistry of soluble guanylate cyclase. Handb. Exp. Pharmacol. 17-31.
15. Dostmann, W. R., Taylor, M. S., Nickl, C. K., Brayden, J. E., Frank, R., and Tegge, W. J. (2000). Highly specific, membrane-permeant pep-tide blockers of cGMP-dependent protein kinase Ialpha inhibit NO-induced cerebral dilation. Proc. Natl. Acad. Sci. U.S.A. 97,14772-14777.
16. Francis, S. H., Turko, I. V., and Corbin, J. D. (2001). Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65, 1-52.
17. Friebe, A., and Koesling, D. (2003). Regulation of nitric oxide-sensitive guanylyl cyclase. Circ. Res. 93, 96-105.
18. Garthwaite, J. (2005). Dynamics of cellular NO-cGMP signaling. Front. Biosci. 10,1868-1880.
19. Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D., and Alexander, R. W. (1994). Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74, 1141-1148.
20. Griffith, T. M., Edwards, D. H., Lewis, M. J., Newby, A. C., and Henderson, A. H. (1984). The nature of endothelium-derived vascular relaxant factor. Nature 308, 645-647.
21. Griffiths, C., Wykes, V., Bellamy, T. C., and Garthwaite, J. (2003). A new and simple method for delivering clamped nitric oxide concentrations in the physiological range: application to activation of guanylyl cyclase-coupled nitric oxide receptors. Mol. Pharmacol. 64, 1349-1356.
22. Hakim, T. S., Sugimori, K., Camporesi, E. M., and Anderson, G. (1996). Half-life of nitric oxide in aqueous solutions with and without haemoglobin. Physiol. Meas. 17, 267-277.
23. Halvey, E. J., Vernon, J., Roy, B., and Garthwaite, J. (2009). Mechanisms of activity-dependent plasticity in cellular no-cGMP signaling. J. Biol. Chem. 284,25630-25641.
24. Ignarro, L. J., Buga, G. M., Byrns, R. E., Wood, K. S., and Chaudhuri, G. (1988). Endothelium-derived relaxing factor and nitric oxide possess identical pharmacologic properties as relaxants of bovine arterial and venous smooth muscle. J. Pharmacol. Exp. Ther. 246, 218-226.
25. Ignarro, L. J., Buga, G. M., Wood, K. S., Byrns, R. E., and Chaudhuri, G. (1987). Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 84, 9265-9269.
26. Kass, D. A., Champion, H. C., and Beavo, J. A. (2007). Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ. Res. 101, 1084-1095.
27. Kemp-Harper, B., and Schmidt, H. H. (2009). cGMP in the vasculature. Handb. Exp. Pharmacol. 191, 447-467.
28. Lowenstein, C. J., and Michel, T. (2006). What';s in a name? eNOS and ana-phylactic shock. J. Clin. Invest. 116, 2075-2078.
29. Matchkov, V. V., Aalkjaer, C., and Nilsson, H. (2004). A cyclic GMP-dependent calcium-activated chloride current in smooth-muscle cells from rat mesenteric resistance arteries. J. Gen. Physiol. 123, 121-134.
30. Moncada, S., Palmer, R. M., and Higgs, E. A. (1991a). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43, 109-142.
31. Moncada, S., Rees, D. D., Schulz, R., and Palmer,R.M. (1991b).Development and mechanism of a specific super-sensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc. Natl. Acad. Sci. U.S.A. 88,2166-2170.
32. Mullershausen, F., Friebe, A., Feil, R., Thompson, W J., Hofmann, F., and Koesling, D. (2003). Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J. Cell Biol. 160, 719-727.
33. Mullershausen, F., Russwurm, M., Thompson, W J., Liu, L., Koesling, D., and Friebe, A. (2001). Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodi-esterase type 5 paralleled by phos-phorylation of the enzyme. J. Cell Biol. 155,271-278.
34. Nakamura, K., Fushimi, K., Kouchi, H., Mihara, K., Miyazaki, M., Ohe, T., and Namba, M. (1998). Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 98, 794-799.
35. Nausch, L. W., Ledoux, J., Bonev, A. D., Nelson, M. T., and Dostmann, W R. (2008). Differential patterning of cGMP in vascular smooth muscle cells revealed by single GFP-linked biosensors. Proc. Natl. Acad. Sci. U.S.A. 105, 365-370.
36. Nickl, C. K., Raidas, S. K., Zhao, H., Sausbier, M., Ruth, P., Tegge, W., Brayden, J. E., and Dostmann, W R. (2010). (d)-Amino acid analogues of DT-2 as highly selective and superior inhibitors of cGMP-dependent protein kinase Ialpha. Biochim. Biophys. Acta 1804, 524-532.
37. NIH. (2011). High Blood Pressure. Bethesda, MD: National Heart Lung and Blood Institute. Available at: www. nhlbi.nih.gov/health/dci/Diseases/ Hbp/HBP_WhatIs.html [accessed July 22, 2011].
38. Palmer, R. M., Ferrige, A. G., and Moncada, S. (1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327, 524-526.
39. Roy, B., and Garthwaite, J. (2006). Nitric oxide activation of guanylyl cyclase in cells revisited. Proc. Natl. Acad. Sci. U.S.A. 103, 12185-12190.
40. Roy, B., Halvey, E. J., and Garthwaite, J. (2008). An enzyme-linked receptor mechanism for nitric oxide-activated guanylyl cyclase. J. Biol. Chem.283, 18841-18851.
41. Rybalkin, S. D., Bornfeldt, K. E., Son-nenburg, W K., Rybalkina, I. G., Kwak, K. S., Hanson, K., Krebs, E. G., andBeavo,J.A. (1997).Calmodulin-stimulated cyclic nucleotide phospho diesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative pheno-type.J. Clin. Invest. 100,2611-2621.
42. Rybalkin, S. D., Rybalkina, I. G., Feil, R., Hofmann, F., and Beavo, J. A. (2002). Regulation of cGMP-specific phos-phodiesterase (PDE5) phosphoryla-tion in smooth muscle cells. J. Biol. Chem. 277, 3310-3317.
43. Rybalkin, S. D., Rybalkina, I. G., Shimizu-Albergine, M., Tang, X. B., and Beavo, J. A. (2003). PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J. 22,469-478.
44. Sausbier, M., Schubert, R., Voigt, V., Hirneiss, C., Pfeifer, A., Korth, M., Kleppisch, T., Ruth, P., and Hofmann, F. (2000). Mechanisms of NO/cGMP-dependent vasorelax-ation. Circ. Res. 87, 825-830.
45. Schlossmann, J., Ammendola, A., Ashman, K., Zong, X., Huber, A., Neubauer, G., Wang, G. X., Allescher, H. D., Korth, M., Wilm, M., Hofmann, F., and Ruth, P. (2000). Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase Ibeta. Nature 404, 197-201.
46. Stone, J. R., and Marletta, M. A. (1996). Spectral and kinetic studies on the activation of soluble guanylate cyclase by nitric oxide. Biochemistry 35, 1093-1099.
47. Waldman, S. A., and Murad, F. (1987). Cyclic GMP synthesis and function. Pharmacol. Rev. 39, 163-196.
48. WHOIS. (2011). Cardiovascular Diseases (CVDs) Fact Sheet No. 317. Geneva: World Health Organization. Available at: http://www.who.int/mediacentre/factsheets/fs317/en/index.html [accessed July 22,2011].
49. Wood, K. C., Batchelor, A. M., Bartus, K., Harris, K. L., Garthwaite, G., Vernon, J., and Garthwaite, J. (2011). Pico-molar nitric oxide signals from central neurons recorded using ultrasensitive detector cells. J. Biol. Chem. 286,43172-43181.
50. Wykes, V., and Garthwaite, J. (2004). Membrane-association and the sensitivity of guanylyl cyclase-coupled receptors to nitric oxide. Br. J. Pharmacol. 141, 1087-1090.